Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C H Ballow

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Diagnostic Microbiology and Infectious Disease|May 23, 1998
In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysisR N Jones, C H Ballow, J J Schentag, et al.
Diagnostic Microbiology and Infectious Disease|December 24, 1997
Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA. SPAR Study GroupC H Ballow, R N Jones, D M Johnson, et al.
The Brazilian Journal of Infectious Diseases : an Official Publication of the Brazilian Society of Infectious Diseases|April 6, 2001
Antimicrobial susceptibility of quinupristin/dalfopristin tested against gram-positive cocci from Latin America: results from the global SMART (GSMART) surveillance studyH S Sader, R N Jones, C H Ballow, et al.
Antimicrobial Agents and Chemotherapy|May 1, 1993
Pharmacodynamics of intravenous ciprofloxacin in seriously ill patientsA Forrest, D E Nix, C H Ballow, et al.
Antimicrobial Agents and Chemotherapy|March 28, 1998
Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapyJ K Thomas, A Forrest, S M Bhavnani, et al.
Diagnostic Microbiology and Infectious Disease|March 24, 2000
A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremiaS M Bhavnani, J A Drake, A Forrest, et al.
The Journal of Antimicrobial Chemotherapy|March 17, 2000
Comparison of the abilities of grepafloxacin and clarithromycin to eradicate potential bacterial pathogens from the sputa of patients with chronic bronchitis: influence of pharmacokinetic and pharmacodynamic variablesJ Q Tran, C H Ballow, A Forrest, et al.
The Annals of Pharmacotherapy|July 1, 1994
Mathematical examination of dual individualization principles (II): The rate of bacterial eradication at the same area under the inhibitory curve is more rapid for ciprofloxacin than for cefmenoximeT F Goss, A Forrest, D E Nix, et al.
Diagnostic Microbiology and Infectious Disease|March 1, 1993
Changes in antimicrobial agent usage resulting from interactions among clinical pharmacy, the infectious disease division, and the microbiology laboratoryJ J Schentag, C H Ballow, A L Fritz, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Diagnostic Microbiology and Infectious Disease|May 23, 1998
In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysisR N Jones, C H Ballow, J J Schentag, et al.
Diagnostic Microbiology and Infectious Disease|December 24, 1997
Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA. SPAR Study GroupC H Ballow, R N Jones, D M Johnson, et al.
The Brazilian Journal of Infectious Diseases : an Official Publication of the Brazilian Society of Infectious Diseases|April 6, 2001
Antimicrobial susceptibility of quinupristin/dalfopristin tested against gram-positive cocci from Latin America: results from the global SMART (GSMART) surveillance studyH S Sader, R N Jones, C H Ballow, et al.
Antimicrobial Agents and Chemotherapy|May 1, 1993
Pharmacodynamics of intravenous ciprofloxacin in seriously ill patientsA Forrest, D E Nix, C H Ballow, et al.
Antimicrobial Agents and Chemotherapy|March 28, 1998
Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapyJ K Thomas, A Forrest, S M Bhavnani, et al.
Diagnostic Microbiology and Infectious Disease|March 24, 2000
A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremiaS M Bhavnani, J A Drake, A Forrest, et al.
The Journal of Antimicrobial Chemotherapy|March 17, 2000
Comparison of the abilities of grepafloxacin and clarithromycin to eradicate potential bacterial pathogens from the sputa of patients with chronic bronchitis: influence of pharmacokinetic and pharmacodynamic variablesJ Q Tran, C H Ballow, A Forrest, et al.
The Annals of Pharmacotherapy|July 1, 1994
Mathematical examination of dual individualization principles (II): The rate of bacterial eradication at the same area under the inhibitory curve is more rapid for ciprofloxacin than for cefmenoximeT F Goss, A Forrest, D E Nix, et al.
Diagnostic Microbiology and Infectious Disease|March 1, 1993
Changes in antimicrobial agent usage resulting from interactions among clinical pharmacy, the infectious disease division, and the microbiology laboratoryJ J Schentag, C H Ballow, A L Fritz, et al.
Pageof 3